authors
-
Zbigniew Wolski, Tomasz Drewa
- Katedra i Klinika Urologii Akademii Medycznej im. L. Rydygiera w Bydgoszczy
Kierownik: prof. dr hab. med. Z. Wolski
keywords
-
prostate programmed cell death (apoptosis)
summary
- Programmed cell death occurs in process named apoptosis. Apoptosis takes
- place in every cell during physiological or pathological state as well. The aim
- of this paper is presentation of the newest achievement in the field of apoptotic
- research regard to pathology of prostate. New possibilities to explain the
- etiology of prostatic pathologic conditions, prevention and menagement of
- BPH and carcinoma of prostate as well.
references
- [1] Agus, D. B., Cordon- Cardo, C, Fox, W., Drobnjak, M., Koff, A., Golde,
- D. W., Schwer, H. I.: Prostate cancer cell cycle regulators: response to androgen
- withdrawal and development of androgen independence. J. Nat. Cancer Inst. 1999,
- 91, 1869-1876.
- [2] Ahonen, T. J., Harkonen, P. L., Laine, J., Rui, H., Martikainen, P. M.,
- Nevalainen, M. T.: Prolaktin is a survival factor for androgen-deprived rat dorsal
- and lateral prostate epithelium in organ culture. Endocr. 1999,140, 5412-5421.
- [3] Blutt, S. R., McDonnell, T. J., Polek, T. C, Weigel, N. L.: Cakitnol-induced
- apoptosis in LNCaP cells is blocked by overexpression ofBcl-2. Endocr. 2000,141,
- 107.
- [4] Bostwik, D. G., Neumann, R., Qian, J., Cheng, L.: Reuersibility of prostatic
- intraepithe³ial neoplasia: Implications for chemoprevention. Eur. Urol. 1999, 35,
- 492-495.
- [5] Cardillo, M., Berchem, G., Tarkington, M. A., Krajewski, S., Krajewski,
- M., Reed, J.-C, Tehan, T., Ortega, L., Lagê, J., Gelmann, E. P: Resistance to
- apoptosis and up regulation of Bcl-2 in benign prostatic hyperplasia after androgen
- deprwation. J. Urol. 1997,158, 212-216.
- [6] Chen, Y. R., Zhou, G., Tan, T. H.: c-Jun N-terminal kinase mediates apoptotic signah
- ing induced by N-(4-hydroxyphenyl)retinamide. Mol. Pharmacol. 1999,56,1271-
- 1279.
- [7] Choi, N. G., Sohn, J. H., Park, H. W., Jung, T. Y.: Apoptosis and nuclear
- shapes in benign prostate hyperplasia and prostate adenocarcinoma: Comparison with
- and relation to Gleason score. Int. J. Urol. 1999, 6,13-18.
- [8] Chon, J. K., Borkowski, A., Partin, A. W., Isaacs, J. T., Jacobs, S. C,
- Kyprianou, N.: Alpha l-adrenoceptor antagonists terazosin anddoxazosin induce
- prostate apoptosis without affecting cell proliferation in patients with benign prostat-
- ic hyperplasia. J. Urol. 1999, 161, 2002-2008.
- [9] Claus, S., Berges, R., Senge, T., Schulze, H.: Celli kinetic in epithelium and
- strorna of benign prostatic hyperplasia. J. Urol. 1997,158, 217-221.
- [10] Colombel, M., Vacherot, F., Diez, S. G., Fontaine, E., Buttyan, R., Chopin,
- D.: Zonal variation of apoptosis and proliferation in the normal prostate and in
- benign prostatic hyperplasia. Br. J. Urol. 1998, 82, 380-385.
- [11] Costa-Pereira, A. P., Cotter, T. G.: Camptothecin sensitizes androgen-indepen-
- dent prostate cancer cells to anti-F as-induced apoptosis. Br. J. Cancer 1999,80,371-
- 378.
- [12] Garzotto, M., Haimovitz-Friedman, A., Liao, W. C, White-Jones, M,
- Huryk, R., Heston, W. D., Cardon-Cardo, C, Kolesnick, R., Fuks, Z.:
- Reversal of radiation resistance in LNCaP cells by targeting apoptosis through cera-
- mide synthase. Cancer Res. 1999, 15, 5194-5201.
- [13] Gjertsen, B. T., Logothetis, Ch. J., McDonnell, T. J.: Molecular regulation of
- cell death and the rapeutic strategies for cell death induction in prostate carcinoma.
- Cancer Metast. Rev. 1999,17, 345-351.
- [14] Gleave, M. E., Miayake, H., Goldie, J., Nelson, C, Tolcher, A.: Targeting
- bcl-2 gene using to delay androgen-independent progression and enhance chemosen-
- sitivity in prostate cancer using antisense bcl-2 oligodeoxynucleotides. Urol. 1999,
- 54 (6A Suppl.), 36-46.
- [15] Gleave, M., Tolcher, A., Miyake, H., Nelson, C, Brown, B., Beraldi, E.,
- Goldie, J.: Progression to androgen independence is delayed by adjuvant treatment
- with antisense Bcl-2 oligodeoxynucleotides after castration in the LNCaP prostate
- tumor model. Clin. Cancer Res. 1999, 5, 2891-2898.
- [16] Gosden, R., Spears, N.: Programmed cell death in the reproductive system. Br.
- Med. Bull. 1997, 5, 644-661.
- [17] Grace, M. J., Xie, L., Musco, M. L., Cui, S., Gumani, M., DiGiacomo, R.,
- Chang, A., Indelicato, S., Syed, J., Johnson, R., Nielsen, L. L.: The use of
- laser scanning cytometry to assess depth of penetration ofadenovirus p53 gene ther-
- apy in human xenograft biopsies. Am. J. Path. 1999,155,1869-1878.
- [18] Grant, E. S., Ross, M. B., Ballard, S., Naylor, A., Habib, F. K.: The insulin-
- like growth type I receptor stimulates growth and suppresses apoptosis in prostatic
- stromal cells. J. Clin. Endocr. Metab. 1998, 83, 3252-3257.
- [19] Haussler, O., Epstein, J. I., Amin, M. B., Heitz, P. U., Hailemariam, S.:
- Cell proliferation, apoptosis, oncegene, and tumor suppresor gene status in adenosis
- with comparison to benign prostatic hyperplasia, prostatic intraepithelial neoplasia,
- and cancer. Hum. Path. 1999, 30,1077-1086.
- [20] Kajiwara, T., Takeuchi, T., Ueki, T., Moriyama, N., Ueki, K., Kakizoe, T.,
- Kawabe, K.: Effect of Bcl-2 overexpression in human prostate cancer cells in vitro
- and in vivo. Int. J. Urol. 1999, 6, 520-525.
- [21] Kelloff, G. J., Lieberman, R., Steele, V. E., Boone, Ch. W., Lubet, R. A.,
- Kopelovitch, L., Malone, W. A., Crowell, J. A., Sigman, C. C: Chemopre-
- vention of prostate cancer: concepts and strategies. Eur. Urol. 1999,35,342-350.
- [22] Krajewska, M., Krajewski, S., Epstein, J. I., Shabaik, A., Sauvageot, J.,
- Song, K., Kitada, S., Reed, J. C: Immunohistochemical analysis of bcl-2, bax, bcl-
- X, and mci-1 expression in prostate cancers. Am. J. Path. 1996,148,1567-1576.
- [23] Krajewski, S., Krajewska, M., Shabaik, A., Miyashita, T., Wang, H. G.,
- Reed, J. C: Immunohistological determination of in vivo distribution of bax, a
- dominant inhibitor of bcl-2. Am. J. Path. 1994,145,1323-1336.
- [24] Kwong, J., Choi, H. E., Huang, Y., Chan, F. L.: Ultrastructural and biochem-
- ical observations on the early changes in apoptotic epithelial cells of the rat prostate
- induced by castration. Cell Tiss. Res. 1999, 298,123-136.
- [25] Kyprianou, N., Litvak, J. P., Borkowski, A., Alexander, R., Jacobs, S. C:
- Induction of prostate apoptosis by doxazosin in benign prostatic hyperplasia. J. Urol.
- 1998, 159, 1810-1815.
- [26] Kyprianou, N., Tu, H., Jacobs, S. C: Apoptotic versus proliferative activities
- in human benign prostatic hyperplasia. Hum. Path. 1996, 27, 668-675.
- [27] Lee, S. H., Shin, M. S., Park, W. S., Kim, S. Y., Dong, S. M., Lee, H. K.,
- Park, J. Y., Oh, R. R., Jang, J. J., Lee, I. Y., Yoo, N. J.: Immunohistochemical
- analysis of fas ligand expression in normal human tissues. APMIS1999,107,1013-
- 1019.
- [28] Lee, C, Sintich, S. M., Mathews, E. P., Shah, A. H., Kundu, S. D., Perry,
- K. T., Cho, J. S., Ilio, K. Y., Cronauer, M. V., Janulis, L., Sensibar, J. A.:
- Transforming growth factor- beta in benign and malignant prostate. Prostate 1999,
- 39, 285-290.
- [29] Li, C. J., Li, Y. Z., Pinto, A. V., Pardee, A. B.: Potent inhibition of tumor
- survival in vivo by beta-lapachone plus taxoh combining drugs imposes different
- artificial checkpoints. Proc. Nat. Acad. Sci. 1999, 96,1369-1374.
- [30] Lim, J. T., Piazza, G. A., Han, E. K., Delohery, T. M., Li, H., Finn, T. S.,
- Buttyan, R., Yamamoto, H,, Sperl, G. J., Brendel, K., Gross, P. H., Pam-
- ukcu, R., Weinstein, I. B.: Sulindac derivatives inhibit growth and induce apopto-
- sis in human prostate cancer cell lines. Biochem. Pharm. 1999,58,1097-1107.
- [31] Lu, S., Tsai, S. Y., Tsai, M. J.: Molecular mechanisms of androgen-independent
- growth of human prostate cancer LNCaP-AI cells. Endocr. 1999,140, 5054-5059.
- [32] Magi-Galluzi, C.,'Montironi, R., Cangi, M. G., Wishnow, K., Loda, M.:
- Mitogen-activated protein kinases and apoptosis in PIN. Virchows Arch. 1998,
- 432, 407-413.
- [33] McConkey, D. J., Greene, G., Pettaway, C. A.: Apoptosis resistance increases
- with metastatic potential in cells of the human LNCaP prostate carcinoma line. Can-
- cer Res. 1996, 56, 5594-5599.
- [34] Mikuz, G.: Pathology of prostate cancer. Old problems and new facts. Adv. Clin.
- Path. 1997,1, 21-34.
- [35] Miller, L. J., Marx, J.: Apoptosis. Science 1998, 281,1301.
- [36] Montironi, R., Magi-Galluzzi, C, Fabris, G.: Apoptotic bodies in prostatic
- intraepithelial neoplasia and prostatic adenocarcinoma following total androgen ab-
- lation. Path. Res. Pract. 1995,197, 873-880.
- [37] Montironi, R., Magi-Galluzzi, C. M., Marina, S., Diamanti, L.: Quantita-
- tive characterization of the frequency and location of cell proliferation and death in
- prostate pathology. J. Cell Biochem. Suppl. 1994,19, 238-245.
- [38] Montironi, R., Magi-Galluzzi, C, Scarpelli, M., Giannulis, I., Diaman-
- ti, L.: Occurrence of cell death (apoptosis) in prostatic intraepithelial neoplasia. Vir-
- chows. Arch. Path. Anat. Histopath. 1993, 423, 351-357.
- [39] Moul, J. W.: Angiogenesis, p53, bcl-2 and Ki-67 in the progression of prostate
- cancer after radical prostatectomy. Eur. Urol. 1999, 35, 399-407.
- [40] Myers, R. B., Grizzle, W. E.: Changes in biomarker expression in the develop-
- ment of prostatic adenocarcinoma. Biotech. Histochem. 1977, 72,86-95.
- [41] Nickerson, T., Pollak, M.: Bicalutamide (Casodex)-induced prostate regression
- involves increased expression of genes encoding insulin-like growth factor binding
- proteins. Urology 1999, 54, 1120-1125.
- [42] Nupponen, N., Visakorpi, T.: Molecular biology of progression of prostate can-
- cer. Eur. Urol. 1999, 35, 351-354.
- [43] Powell, W. C, Fingletpn, B., Wilson, C. L., Boothby, M., Matrisian, L.
- M.: The metalloproteinase matrilysin proteolytically generates active soluble fas ligand
- and potentiates epithelial cell apoptosis. Curr. Biol. 1999, 9,1441-1447.
- [44] Radziszewska, E.: Fizjologiczna rolaapoptozy. Post. Biol. Kom. 1995,22,247-
- 261.
- [45] Rajah, R., Khare, A., Lee, P. D., Cohen, P.: Insulin-like growth factor-binding
- protein-3 is partially responsible for high-serum-induced apoptosis in PC-3 prostate
- cancer cells. J. Endocr. 1999,163,487-494.
- [46] Reuter, V. R.: Pathological changes in benign and malignant prostatic tissue follow-
- ing androgen deprovation therapy. Urology 1997, 49 (3A Suppl.), 16-22.
- [47] Rittmaster, R. S., Nonnan, R. W., Thomas, L. N., Rowden, G.: Evidence for
- atrophy and apoptosis in the prostates of men given finasteride. J. Clin. Endrocrinol.
- Metab. 1996, 81, 814-819.
- [48] Rittmaster, R. S., Thomas, L. N., Wright, A. S., Murray, S. K., Carlson,
- K., Douglas, R. C, Yung, J., Messich, M., Bell, D., Lazier, C. B.: Theutility
- of tissue transglutaminase as a marker of apoptosis during treatment and progression
- of prostate cancer. J. Urol. 1999,162, 2165-2169.
- [49] Rokhlin, O. W., Bishop, G. A., Hostager, B. S., Waldschmidt, T. I., Si-
- dorenko, S. P., Pavloff, N., Kiefer, M. C, Umansky, S. R., Glover, R. A.,
- Cohen, M. B.: Fas-mediated apoptosis in human prostatic carcinoma cell lines.
- Cancer Res. 1997, 57f 1758-1768.
- [50] Rokhlin, O. W., Glover, R.A., Cohen, M. B.: Fas-mediated apoptosis in human
- prostatic carcinoma cell lines occurs via activation ofcaspase-8 and caspase-7. Can-
- cer Res. 1998, 58, 5870-5875.
- [51] Rokhlin, O. W., Hostager, B. S., Bishop, G. A., Sidorenko, S. P., Glover,
- R. A., Gudkov, A. V., Cohen, M. B.: Dominant nature of the resistance tofas-and
- tumor necrosis factor-alfa-mediated apoptosis in human prostatic carcinoma cell lines.
- Cancer Res. 1997, 57, 3941-3943.
- [52] Rose, D. P., Connolly, J. M.: Omega-3 fatty acids as cancer chemopreventive
- agents. Pharm. Ther. 1999, 83, 217-244
- [53] Riuz, L., Miguel, A., Diaz-Laviada, I.: Delta ^-tetrahydrocannabinol induced
- apoptosis in human prostate PC- 3 cells via a receptor-independent mechanism. FEBS
- Lett. 1999, 458, 400-404.
- [54] Savill, J.: Recognition and phagocytosis of cells undergoing apoptosis. Br. Med.
- Bull. 1995, 53, 491-508.
- [55] Shibata, M. A., Ward, J. M., Devor, D. E., Liu, M. L., Green, J. E.: Progres-
- sion of prostatic intraepithelial neoplasia to invasive carcinoma in C3(l)/SV40 large
- T antigen transgenic mice: histopathological and molecular biological alterations.
- Cancer Res. 1999, 56, 4894-4903.
- [56] Shim, M., Cohen, P.: IGFs and human cancer: implications regarding the risk of
- growth hormone therapy. Horm. Res. 1999,51 (Suppl. S3), 42-51.
- [57] Srikanth, S., Franklin, C. C, Duke, R. C, Kraft, R. S.: Human DU145
- prostate cancer cells overexpressing mitogen-activated protein kinase phosphatase -1
- are resistant to fas ligand-induced mitochondrial perturbations and cellular. Mol.
- Cell Biochem. 1999,199,169-178.
- [58] Stattin, P., Damber, J. E., Karlberg, L., Nordgren, H., Bergh, A.: Bcl-2
- immunoreaclivity in prostate tumorgenesis in relation to prostatic intraepithelial
- neoplasia, grade, hormonal status, metastatic growth and survival. Urol. Res. 1996,
- 24, 257-264.
- [59] Stattin, P., Westin, P., Damber, J. H., Bergh, A.: Short-term cellular effects
- induced by castration therapy in relation to clinical outcome in prostate cancer. Br. J.
- Cancer 1998, 77, 670-675.
- [60] Steinberg, J., Oyasu, R., Lang, S., Sinlich, S., Rademaker, A., Lee, C,
- Kozlowski, J. M., Sensibar, J. A.: Intracellular levels of'SGP-2 (Clusterin) corre-
- late with tumor grade in prostate cancer. Clin. Cancer Res. 1997, 3,1707-1711.
- [61] Steller, H.: Mechanism and genes of cellular suside. Science 1995, 267, 1445-
- 1449.
- [62] Sumimoto, M., Tachibana, M., Nakashima, J., Murai, M., Miyajima, A.,
- Kimura, F., Hayakawa, M., Nakamura, H.: An essential role for nuclear factor
- kappa B in preventing TNF-alfa induced cell death in prostate cancer cells. J. Urol.
- 1999, 161, 674-679.
- [63] Sun, Z. Y., Wu, H. Y., Wang, M. Y., Tu, Z. H.: The mechanism ofepristeride
- agains benign prostatic hyperplasia. Eur. J. Pharm. 1999, 371, 227-233.
- [64] Szende, B., Romics, I., Torda, I., Bely, M., Szegedi, Z., Lovasz, S.: Apopto-
- sis, mitosis, p53, bcl(2), Ki-67 and clinical outcome in prostate carcinoma treated by
- androgen ablation. Urol. Int. 1999, 63,115-119.
- [65] Taboga, S. R.: Apoptosis as a mediator of hyperplastic recovery in human prostate
- lesions: cytochemical and immunocytochemical evaluation. Cytobios. 1999, 99,19-
- 26.
- [66] Tang, D. G., Li, L., Chopra, D. P., Porter, A. T.: Extended survivability of
- prostate cancer cells in the absence of tropic factors: incresed proliferation, evansion of
- apoptosis, and the role of apoptosis proteins. Cancer Res. 1998, 58, 3466-3479.
- [67] Thornberry, N. A., Lazebnik, Y.: Caspases: enemies within. Science 1998,281,
- 1312-1316.
- [68] Wang, X. Z., Beebe, J. R., Pwiti, L. Bielawska, A., Smyth, M. J.: Aberrant
- sphingolipid signaling is involved in the resistance of prostate cancer cell lines to
- chemotherapy. Cancer Res. 1999, 59, 5842-5848.
- [69] Webber, M. M., Bello-De-Ocampo, D., Quader, S., Deocampo, N. D., Met-
- calfe, W. S., Sharp, R. M.: Modulation of the malignant phenotype of human
- prostate cancer cells by N-(4-hydroxyphenyl) retinamide (4-HPR). Clin. Exp. Metast.
- 1999, 17, 255-263.'
- [70] Wheeler, T. M., Rogers, E., Aihara, M., Scardino, P. T., Thompson, T. C:
- Apoptotic index as a biomarker in prostatic intraepithelial neoplasia (PIN) and pros-
- tate cancer. J. Cell Biochem. Suppl. 1994,19, 202-207.
- [71] Whelan, P.: Retinoids in chemoprevention. Eur. Urol. 1999, 35, 424-428.
- [72] Yang, G., Timme, T. L., Park, S. H., Wu, X., Wyllie, M. G., Thompson, T.
- C: Transformating growth factorbeta I transduced mouse prostate reconstituctions:
- II. Induction of apoptosis by doxazosin. Prostate 1997, 33,157-163.
- [73] Ying, S. Y., Chuong, C. M., Lin, S.: Suppression ofactivin-induced apoptosis by
- novelantisense strategy in human prostate cancer cells. Biochem. Biophys. Res.
- Commun. 1999, 26, 669-673.
|